rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RCKT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Rocket Pharmaceuticals: Progress Is Encouraging, But Clinical Validation Still Matters

      Analyst rates Rocket Pharmaceuticals a Hold: KRESLADI onboarding and cardiovascular validation must advance before a bullish view; shares trade at 0.71x...

      Nov 14Seeking AlphaRCKT
      Rocket Pharma updates progress on RP-A501 for Danon disease

      Rocket Pharmaceuticals charts pivotal Phase 2 path for Danon disease gene therapy RP-A501. Read more here.

      Oct 7Seeking AlphaRCKT
      Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility
      Oct 7Yahoo FinanceRCKT
      Rocket Pharma outlines path for Danon disease gene therapy
      Oct 7Investing.comRCKT
      Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
      Oct 7Yahoo FinanceRCKT
      Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data - Slideshow (NASDAQ:RCKT) 2026-10-07
      Oct 7Seeking AlphaRCKT
      Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
      Oct 7Yahoo FinanceRCKT
      Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

      CRANBURY, N.J., October 06, 2026--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $150 million. The facility strengthens Rocket’s financial position and provides access to additional capital to support executi

      Oct 6Yahoo FinanceRCKT
      Rocket Pharma stock upgraded at Needham (RCKT:NASDAQ)

      Rocket Pharmaceuticals (RCKT) stock gains as Needham upgrades the company to Buy after FDA alignment on a pivotal Phase 2 trial for a Danon disease.drug. Read more here.

      Sep 16Seeking AlphaRCKT
      RCKT Aligns With FDA on Completing Phase II Study in Danon Disease

      Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.

      Sep 16Yahoo FinanceRCKT
      Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock

      Needham said the FDA outcome was better than expected because the regulator could have demanded meaningful changes to Rocket’s Danon disease trial.

      Sep 16Yahoo FinanceRCKT
      Rocket Pharmaceuticals at Morgan Stanley conference: danon trial clears key hurdle
      Sep 15Investing.comRCKTMS
      Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights

      The FDA confirmed continued enrollment and dosing under the modified trial protocol after reviewing safety data from the first three patients treated at the recalibrated dose.

      Sep 15Yahoo FinanceRCKT
      Rocket Pharmaceuticals stock jumps on FDA trial alignment
      Sep 15Investing.comRCKT
      Rocket Pharma gets FDA alignment on Danon disease trial
      Sep 15Investing.comRCKT
      Rocket Pharmaceuticals general counsel sells $256,463 in RCKT shares
      Sep 15Investing.comRCKT
      Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating
      Sep 1Investing.comRCKT

      This is the newest page. Registered accounts read further back.